anlotinib + liposomal doxorubicin

Anlotinib + liposomal doxorubicin is a combination therapy consisting of anlotinib, a novel oral small molecule multi-targeted tyrosine kinase inhibitor, and liposomal doxorubicin, a pegylated formulation of the anthracycline chemotherapeutic agent doxorubicin. Anlotinib inhibits multiple targets involved in tumor angiogenesis and proliferation, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptors (PDGFR), and c-Kit. Liposomal doxorubicin delivers cytotoxic activity by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis in rapidly dividing cells. The combination has been investigated primarily for the treatment of locally advanced or metastatic soft tissue sarcoma (STS). Clinical studies have shown that this regimen can achieve objective response rates around 25–40% with disease control rates up to 80%, and median progression-free survival ranging from approximately 7 to 11 months. Most adverse events are manageable; common grade 3/4 toxicities include leukopenia, hand-foot syndrome, anemia, and febrile neutropenia[1][3][4][6][9].

Brand names

anlotinibAL3818AL-3818AL 3818Caelyx

Other names

anlotinibAL3818AL-3818AL 3818pegylated liposomal doxorubicinPLDCaelyxliposomal doxorubicin